

Physician: Doctor, Example

## Patient: Patient, Example

| DOB                     | 11/28/1959              |
|-------------------------|-------------------------|
| Gender:                 | Female                  |
| Patient Identifiers:    | 01234567890ABCD, 012345 |
| Visit Number (FIN):     | 01234567890ABCD         |
| <b>Collection Date:</b> | 00/00/0000 00:00        |

## B-Lymphoblastic Leukemia (B-ALL) Minimum Residual Disease Detection by Flow Cytometry ARUP test code 3000724

| Number of Markers        | 10 markers  |
|--------------------------|---|
| B-All MRD Interpretation | See Note  |
|                          | SAMPLE: Bone Marrow   |
|                          | IMPRESSION:<br>NEGATIVE for persistent/recurrent B lymphoblastic<br>leukemia/lymphoma by flow cytometry (see comment).  |
|                          | COMMENT:<br>The limit of detection of this assay is estimated to be 0.0054%.  |
|                          | 1. The atypical immature B-lineage cells reported in a previous<br>peripheral blood flow cytometry study from 11-11-2022 (Accession<br>#22-315-126465) were not detected in this study.<br>2. A concurrent bone marrow LL PANEL flow cytometry study is<br>reported under Accession #23-331-120594. |
|                          | ANALYSIS:<br>Total viable leukocytes collected: 1,399,530<br>Estimated specimen viability (fs/ss): 91%  |
|                          | Antigens examined: CD10, CD19, CD20, CD22, CD24, CD34, CD38,<br>CD45, CD58, CD66b   |
|                          | Number of markers assessed:10   |
|                          | This result has been reviewed and approved by <b>second second</b> 11/29/2023   |
|                          | INTERPRETIVE INFORMATION: B-ALL MRD by Flow Cytometry   |
|                          | This test was developed and its performance characteristics<br>determined by ARUP Laboratories. It has not been cleared or<br>approved by the US Food and Drug Administration. This test was<br>performed in a CLIA certified laboratory and is intended for<br>clinical purposes.                  |

| VERIFIED/REPORTED DATES |                  |                     |                              |  |
|-------------------------|------------------|---------------------|------------------------------|--|
| Accession               | Collected        | Received            | Verified/Reported            |  |
| 23-331-120594           | 00/00/0000 00:00 | 00/00/0000 00:00    | 00/00/0000 00:00             |  |
|                         |                  | Accession Collected | Accession Collected Received |  |

## H=High, L=Low, \*=Abnormal, C=Critical



800-522-2787 | aruplab.com 500 Chipeta Way, Salt Lake City, UT 84108-1221 Jonathan R. Genzen, MD, PhD, Chief Medical Officer

| Leuk/Lymph Phenotype, Source | 23-331-120594 | 00/00/0000 00:00 | 00/00/0000 00:00 | 00/00/0000 00:00 |
|------------------------------|---------------|------------------|------------------|------------------|
| Number Of Markers            | 23-331-120594 | 00/00/0000 00:00 | 00/00/0000 00:00 | 00/00/0000 00:00 |
| Number of Markers            | 23-331-120594 | 00/00/0000 00:00 | 00/00/0000 00:00 | 00/00/0000 00:00 |
| B-All MRD Interpretation     | 23-331-120594 | 00/00/0000 00:00 | 00/00/0000 00:00 | 00/00/0000 00:00 |

## END OF CHART

H=High, L=Low, \*=Abnormal, C=Critical